These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 35040089

  • 1. Prioritizing the Catalytic Gatekeepers through Pan- Inhibitory Mechanism of Entrectinib against ALK, ROS1 and TRKA Tyrosine Kinases.
    Salifu EY, Issahaku AR, Agoni C, Ibrahim MAA, Manimbulu N, Soliman MES.
    Cell Biochem Biophys; 2022 Mar; 80(1):11-21. PubMed ID: 35040089
    [Abstract] [Full Text] [Related]

  • 2. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
    Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P.
    J Med Chem; 2016 Apr 14; 59(7):3392-408. PubMed ID: 27003761
    [Abstract] [Full Text] [Related]

  • 3. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
    Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, Avanzi N, Amboldi N, Saccardo MB, Casero D, Orsini P, Bandiera T, Mologni L, Anderson D, Wei G, Harris J, Vernier JM, Li G, Felder E, Donati D, Isacchi A, Pesenti E, Magnaghi P, Galvani A.
    Mol Cancer Ther; 2016 Apr 14; 15(4):628-39. PubMed ID: 26939704
    [Abstract] [Full Text] [Related]

  • 4. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
    Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG.
    Cancer Discov; 2017 Apr 14; 7(4):400-409. PubMed ID: 28183697
    [Abstract] [Full Text] [Related]

  • 5. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
    Frampton JE.
    Drugs; 2021 Apr 14; 81(6):697-708. PubMed ID: 33871816
    [Abstract] [Full Text] [Related]

  • 6. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
    Ku BM, Bae YH, Lee KY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
    Invest New Drugs; 2020 Apr 14; 38(2):360-368. PubMed ID: 31124056
    [Abstract] [Full Text] [Related]

  • 7. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
    Pacenta HL, Macy ME.
    Drug Des Devel Ther; 2018 Apr 14; 12():3549-3561. PubMed ID: 30425456
    [Abstract] [Full Text] [Related]

  • 8. The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements.
    Delgado J, Pean E, Melchiorri D, Migali C, Josephson F, Enzmann H, Pignatti F.
    ESMO Open; 2021 Apr 14; 6(2):100087. PubMed ID: 33735800
    [Abstract] [Full Text] [Related]

  • 9. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
    Rolfo C, Ruiz R, Giovannetti E, Gil-Bazo I, Russo A, Passiglia F, Giallombardo M, Peeters M, Raez L.
    Expert Opin Investig Drugs; 2015 Apr 14; 24(11):1493-500. PubMed ID: 26457764
    [Abstract] [Full Text] [Related]

  • 10. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia.
    Smith KM, Fagan PC, Pomari E, Germano G, Frasson C, Walsh C, Silverman I, Bonvini P, Li G.
    Mol Cancer Ther; 2018 Feb 14; 17(2):455-463. PubMed ID: 29237803
    [Abstract] [Full Text] [Related]

  • 11. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
    Sartore-Bianchi A, Pizzutilo EG, Marrapese G, Tosi F, Cerea G, Siena S.
    Expert Rev Anticancer Ther; 2020 May 14; 20(5):333-341. PubMed ID: 32223357
    [Abstract] [Full Text] [Related]

  • 12. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
    Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A, Fox E.
    Neuro Oncol; 2022 Oct 03; 24(10):1776-1789. PubMed ID: 35395680
    [Abstract] [Full Text] [Related]

  • 13. Entrectinib, a new multi-target inhibitor for cancer therapy.
    Jiang Q, Li M, Li H, Chen L.
    Biomed Pharmacother; 2022 Jun 03; 150():112974. PubMed ID: 35447552
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors.
    Mercier F, Djebli N, González-Sales M, Jaminion F, Meneses-Lorente G.
    Cancer Chemother Pharmacol; 2022 Mar 03; 89(3):363-372. PubMed ID: 35118559
    [Abstract] [Full Text] [Related]

  • 15. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
    Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC, trial investigators.
    Lancet Oncol; 2020 Feb 03; 21(2):261-270. PubMed ID: 31838015
    [Abstract] [Full Text] [Related]

  • 16. Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date.
    Araujo JM, Gomez AC, Pinto JA, Rolfo C, Raez LE.
    Hematol Oncol Stem Cell Ther; 2021 Sep 03; 14(3):192-198. PubMed ID: 33290717
    [Abstract] [Full Text] [Related]

  • 17. Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusionpositive, Recurrent or Advanced Solid Tumors.
    Osman HM, Tuncbilek M.
    Curr Med Chem; 2022 Sep 03; 29(15):2602-2616. PubMed ID: 34521321
    [Abstract] [Full Text] [Related]

  • 18. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, André F, Soria JC, Friboulet L.
    Clin Cancer Res; 2016 Dec 15; 22(24):5983-5991. PubMed ID: 27401242
    [Abstract] [Full Text] [Related]

  • 19. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A, Casaluce F, Maione P, Gridelli C.
    Expert Rev Anticancer Ther; 2018 Jan 15; 18(1):71-80. PubMed ID: 29187012
    [Abstract] [Full Text] [Related]

  • 20. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
    Nozaki Y, Yamamoto H, Iwasaki T, Sato M, Jiromaru R, Hongo T, Yasumatsu R, Oda Y.
    Hum Pathol; 2020 Dec 15; 106():82-92. PubMed ID: 32980422
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.